BioPorto A/S (CPH: BIOPOR)

Market Cap	637.61M
Revenue (ttm)	34.91M
Net Income (ttm)	-61.30M
Shares Out	429.66M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	261,610
Open	1.580
Previous Close	1.582
Day's Range	1.524 - 1.606
52-Week Range	1.210 - 2.850
Beta	1.25
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1917
• Employees: 29
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BIOPOR

Financial Performance

In 2023, BioPorto's revenue was 30.96 million, an increase of 6.87% compared to the previous year's 28.97 million. Losses were -56.33 million, -25.81% less than in 2022.